Thomas Parsons Email & Phone Number

Boston, Ma, Us

Norwood, Massachusetts, Us

Manage CMC development and outsourced cGMP manufacturing of drug substance, drug product, fill/finish and labeling/packaging for CRB-701 (next-generation Nectin-4 Antibody Drug Conjugate), CRB-601 (monoclonal antibody targeting integrin Alpha5Beta8) to inhibit activation of TGFβ, and CRB-913 (orally available peripherally restricted CB1 reverse agonist)

Germantown, Md, Us

Managed CMC development and outsourced cGMP manufacturing of drug substance, drug product, fill/finish and labeling/packaging for TLY012, a proprietary version of the recombinant human TRAIL protein, for clinical studies.

South San Francisco, Ca, Us

• Managed CMC development and outsourced cGMP manufacturing of drug substance, drug product, fill/finish and labeling/packaging for multiple clinical candidates including: NGM282 (engineered human FGF19), NGM313 (anti-FGFR1c receptor agonistic mAb), NGM386 (engineered GDF15), NGM395 (long acting engineered GDF15), NGM120 (anti GFRAL mAb), NGM217 (mAb) and NGM621 (mAb).• Generated, managed and coordinated CMC timelines and budget with multiple CMOs, CROs and internal teams from CMC, non-clinical development, bioanalytical assay development, clinical development, finance, contracts and business development to enter 7 candidates into the clinic within the last 8 years, and re-supply for proof-of-concept Ph2 studies.

South San Francisco, Ca, Us

• Discovery and development of novel proteins and antibodies as therapeutic drug candidates for metabolic diseases. • Built a multifunctional team of 17 Scientists responsible for expression vector design and development, microbial cell production, mammalian cell production, protein purification and characterization and generation and selection of monoclonal antibodies as therapeutic or reagent antibodies.• Advanced a pipeline of four clinical candidates including: NGM282 (engineered human FGF19), NGM313 (anti-FGFR1c receptor agonistic mAb), NGM386 (engineered GDF15) and NGM395 (long acting engineered GDF15)

New York, New York, Us

• Advanced a pipeline of protein therapeutics through preclinical development and into the clinic within two disease areas: Anti-infectives (HIV, HCV and C. difficile-associated disease) and cancer. Two product candidates advanced into Phase 1, PSMA ADC (PSMA antibody-drug conjugate for prostate cancer) and PSMA-VRP (viral vector vaccine for prostate cancer), and one product candidate advanced into Phase 2, PRO 140 (CCR5 antibody for HIV).• Managed a multifunctional team responsible for generation of mouse hybridomas, mammalian cell production, protein purification, and in vitro and in vivo characterization of monoclonal antibodies and antibody-drug conjugates (including related assays and reagents for potency, and PK and PD).• Co-authored multiple NIH grants to develop specific biologics for the treatment of cancer, HIV, and C. difficile-associated disease.

Cambridge, Ma, Us

• Mammalian cell production, purification and characterization of antibodies and protein reagents for potency, PK, and PD assays to support clinical development programs, Vedolizumab (anti-integrin receptor alpha4beta7 mAb), MLN1202 (anti-chemokine receptor CCR2 mAb), PRO 140 (anti-chemokine receptor CCR5 mAb) (integrin receptor alpha4beta7 antibody) and MLN1202 (chemokine receptor CCR2 antibody) for the treatment of autoimmune diseases.• Generation of monoclonal antibody drug candidates using classical mouse hybridomas, transgenic mouse hybridomas, and phage display for preclinical development programs for oncology indications. • Generated over 30 monoclonal antibody reagents (including phospho-specific mAbs) for cell based mechanism of action studies, pharmacodynamic assays and biomarker assays.• Protein characterization including amino acid analysis, amino terminal sequencing by Edman degradation, LC/MS/MS for identification of post translational modifications and phospho-peptide mapping efforts, and BIACORE. • Expression, purification and characterization of over 110 novel enzyme targets (representing approximately 25 different enzyme classes) produced from insect cells, E.coli. and mammalian cells resulting in successful high-throughput screens to support small molecule drug development.• Outsourced programs for monoclonal antibody generation, screening and selections.

• Large scale fermentation and cell production, and purification of novel enzyme targets (including homologues and orthologues) in E.coli. and insect cell systems resulting in successful high-throughput screens and hit-to-lead efforts for small molecule drugs for oncology indications.

• Formulation, animal model development, and preclinical evaluation of rhBMP-2/absorbable collagen sponge, an osteoinductive protein device for bone repair.

• Generated a pipeline of protein therapeutics including engineered antibodies and antibody drug conjugates for the treatment of cancer, osteoinductive proteins for bone repair, and recombinant protein therapeutics for the treatment of sepsis.• Advanced BMP proteins/hydroxyapatite sponge as an osteoinductive protein device for bone repair into Phase 1. • Developed a portfolio of delivery systems for the use of recombinant proteins in bone repair indications with particular products suitable for particular surgical applications.• Managed a multifunctional team responsible for molecular biology, cell production in mammalian, E.coli and yeast cells, protein purification & characterization.

Structure and mechanism of action of glycoprotein hormones TSH, LH, FSH and hCG.

Ph.D., Biochemistry

B.S., Biochemistry